BRPI0113477B8 - proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula - Google Patents

proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula

Info

Publication number
BRPI0113477B8
BRPI0113477B8 BRPI0113477A BRPI0113477B8 BR PI0113477 B8 BRPI0113477 B8 BR PI0113477B8 BR PI0113477 A BRPI0113477 A BR PI0113477A BR PI0113477 B8 BRPI0113477 B8 BR PI0113477B8
Authority
BR
Brazil
Prior art keywords
delivering
protein
membrane
glycoprotein
oligonucleotide
Prior art date
Application number
Other languages
English (en)
Inventor
C Morse Clarence
A Keesler Goerge Jr
Guo Yong
Yao Zhengbin
Original Assignee
Aventis Holdings Inc
Aventis Pharma Inc
Hmr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Holdings Inc, Aventis Pharma Inc, Hmr Pharma Inc filed Critical Aventis Holdings Inc
Priority claimed from PCT/US2001/026421 external-priority patent/WO2002018572A2/en
Publication of BR0113477A publication Critical patent/BR0113477A/pt
Publication of BRPI0113477B1 publication Critical patent/BRPI0113477B1/pt
Publication of BRPI0113477B8 publication Critical patent/BRPI0113477B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Abstract

"peptídios de penetração em membranas e usos dos mesmos". a presente invenção refere-se a peptídios de penetração em membranas úteis como dispositivos de distribuição intracelular in vivo, ex vivo e in vitro para um composto de interesse. mais particularmente, a invenção envolve a identificação de peptídios de penetração em membranas que podem ser usados como veículos de proteínas para a distribuição de um composto de interesse para células, e métodos de distribuição de um composto de interesse preso aos peptídios de penetração em membranas para células.
BRPI0113477 2000-08-25 2001-08-23 proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula BRPI0113477B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
PCT/US2001/026421 WO2002018572A2 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof

Publications (3)

Publication Number Publication Date
BR0113477A BR0113477A (pt) 2004-04-20
BRPI0113477B1 BRPI0113477B1 (pt) 2019-10-22
BRPI0113477B8 true BRPI0113477B8 (pt) 2021-05-25

Family

ID=22853919

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0113477 BRPI0113477B8 (pt) 2000-08-25 2001-08-23 proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula

Country Status (10)

Country Link
US (2) US20030229202A1 (pt)
JP (1) JP4896356B2 (pt)
KR (1) KR100810927B1 (pt)
AR (1) AR033834A1 (pt)
BR (1) BRPI0113477B8 (pt)
DE (1) DE60133585T2 (pt)
GB (1) GB0103110D0 (pt)
IL (1) IL154589A (pt)
TW (1) TWI317737B (pt)
ZA (1) ZA200301476B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
AU2003214625A1 (en) * 2002-04-08 2003-10-27 Yeda Research And Development Co. Ltd. Histone conjugates and uses thereof
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP1631306A4 (en) * 2003-05-19 2009-08-12 Univ Columbia COMPOSITIONS AND METHODS OF TREATING AND PREVENTING HEART TISSUE DEGENERATION AND THEIR USE
JP2007505621A (ja) * 2004-04-13 2007-03-15 メドトロニック・ソファモア・ダネック 骨誘導タンパク質及びペプチドの細胞内送達
WO2007038492A2 (en) * 2005-09-26 2007-04-05 The Trustees Of Columbia University In The City Of New York Side population cells in cardiac repair
CN101355957A (zh) * 2005-11-04 2009-01-28 为人技术株式会社 将融合多肽递送入细胞的方法
JP2009544688A (ja) * 2006-07-24 2009-12-17 フォーヒューマンテック カンパニー リミテッド 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法
KR100843634B1 (ko) * 2006-08-03 2008-07-03 연세대학교 산학협력단 세포막투과 전달 펩타이드 및 이를 포함하는 생물제제
WO2008047243A2 (en) * 2006-08-29 2008-04-24 Forhumantech. Co., Ltd. Pharmaceutical composition for suppression of apoptosis and method for delivering the same
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
EP2236514B1 (en) * 2008-01-25 2013-04-03 Toagosei Co., Ltd Artificial peptide and use thereof
AU2009215426B2 (en) * 2008-02-21 2015-06-11 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with C-terminal elements
JP5709013B2 (ja) 2009-04-10 2015-04-30 東亞合成株式会社 神経分化誘導ペプチド及びその利用
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
CN102869384B (zh) * 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
JP5858284B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメントとその利用
JP5858285B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673846B2 (en) 2009-11-02 2014-03-18 Toagosei Co. Ltd. Cell proliferation-promoting peptide and use thereof
JP5808082B2 (ja) * 2010-04-30 2015-11-10 株式会社Adeka 細胞への水溶性高分子量物質の導入方法及び導入剤
US9394535B2 (en) 2010-05-25 2016-07-19 National University Corporation Kumamoto University Plasma irradiation device for substance introduction and substance introduction method using plasma irradiation device
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
JP6202707B2 (ja) * 2011-10-13 2017-09-27 国立大学法人鳥取大学 新規細胞膜透過ペプチド
JP6066222B2 (ja) 2012-05-28 2017-01-25 東亞合成株式会社 抗菌ペプチド及びその利用
US20150104873A1 (en) * 2012-07-11 2015-04-16 University of Nevada, Las Vegas Genome Surgery with Paired, Permeant Endonuclease Construct
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
AU2014206792A1 (en) * 2013-01-18 2015-07-23 Glycotope Gmbh Fusion peptides for enhancing protein expression
CN113105559A (zh) 2013-12-12 2021-07-13 生命技术公司 增强转染的膜穿透性肽和组合物以及其使用方法
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
WO2016136708A1 (ja) 2015-02-27 2016-09-01 学校法人常翔学園 膜透過性ペプチドを側鎖に有する高分子化合物
CN107207627B (zh) 2015-02-27 2022-05-24 学校法人常翔学园 具有膜透过性肽链的多糖衍生物
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019157089A1 (en) * 2018-02-06 2019-08-15 University Of Maryland, Baltimore Tlr9 inhibitors to suppress inflammatory response to pathogens
KR102386498B1 (ko) * 2018-12-27 2022-04-15 한양대학교 산학협력단 Crispr-cas를 기반으로 하는 유전자 교정용 조성물
WO2020139031A1 (ko) * 2018-12-27 2020-07-02 한양대학교 산학협력단 Crispr-cas를 기반으로 하는 유전자 교정용 조성물
CN113661239A (zh) 2018-12-28 2021-11-16 催化剂生物科学公司 经修饰的尿激酶型纤溶酶原激活物多肽和使用方法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CN110441156A (zh) * 2019-07-20 2019-11-12 大连理工大学 一种基于土体稳定状态特性测量三轴试样膜嵌入量的方法
CN114716569B (zh) * 2022-04-13 2023-11-10 浙江大学 一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6197925B1 (en) * 1991-08-22 2001-03-06 Sara Lee Corporation NF-AT polypeptides and polynucleotides
US5843643A (en) * 1992-02-21 1998-12-01 Ratner; Paul L. Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
AU1209697A (en) * 1996-08-09 1998-03-06 Dnavec Research Inc. Phage bonded to nuclear location signal
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US5962415A (en) 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
US5929042A (en) 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof
WO1998049325A1 (en) 1997-04-28 1998-11-05 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
FR2767323B1 (fr) 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
SE9801055D0 (sv) * 1998-03-25 1998-03-25 Inst Of Molecul & Cell Biology Use of growth hormone binding protein (GHBP)
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
US6436628B1 (en) * 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
MXPA01000271A (es) 1998-07-13 2002-10-17 Expression Genetics Inc Analogo de poliester de poli-lisina como un portador para el suministro de genes, soluble, biodegradable.
US6246558B1 (en) * 1998-08-24 2001-06-12 Leviton Manufacturing Company Circuit interrupting device with reverse wiring protection
FR2786398B1 (fr) 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
WO2000075669A1 (en) * 1999-06-08 2000-12-14 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins
AU785007B2 (en) 1999-11-24 2006-08-24 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
JP3908425B2 (ja) * 1999-12-24 2007-04-25 アルパイン株式会社 ナビゲーション装置
AU2001275423B2 (en) 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
JP3686961B2 (ja) * 2000-08-04 2005-08-24 シャープ株式会社 液晶表示装置及びそれを用いた電子機器
JP2002304088A (ja) * 2001-04-09 2002-10-18 Ricoh Co Ltd 画像形成装置
CA2477429A1 (en) * 2002-01-29 2003-08-07 Robert A. Uger Targeted immunogens
US6877262B2 (en) * 2003-07-10 2005-04-12 Ronald Bianco Perpetual calendar
DE10341112A1 (de) * 2003-09-05 2005-03-31 Li-Li Yehhsu Behälter mit separaten Speicherkammern
BRPI0418273A (pt) * 2003-12-31 2007-05-02 Sanofi Pasteur Inc imunógenos alvejados

Also Published As

Publication number Publication date
TWI317737B (en) 2009-12-01
DE60133585D1 (de) 2008-05-21
US7754678B2 (en) 2010-07-13
AR033834A1 (es) 2004-01-07
KR20030034156A (ko) 2003-05-01
IL154589A (en) 2011-08-31
JP4896356B2 (ja) 2012-03-14
US20030229202A1 (en) 2003-12-11
DE60133585T2 (de) 2009-06-04
GB0103110D0 (en) 2001-03-28
BR0113477A (pt) 2004-04-20
US20060100134A1 (en) 2006-05-11
JP2004512275A (ja) 2004-04-22
ZA200301476B (en) 2004-06-22
KR100810927B1 (ko) 2008-03-10
BRPI0113477B1 (pt) 2019-10-22

Similar Documents

Publication Publication Date Title
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
AU8524901A (en) Membrane penetrating peptides and uses thereof
ATE312172T1 (de) Immunschützendes influenzaantigen und dessen verwendung zur impfung
US7659252B2 (en) Transdermal delivery peptides and method of use thereof
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
BRPI0416044A (pt) sistema e método para distribuição transdérmica
WO2001091728A3 (en) Nanoemulsion formulations
DE69329903D1 (de) Bioabbaubare polymere zur zelltransplantation
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
BR0316402A (pt) vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
DE69730218D1 (de) Fusogene liposomen
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
WO1996036314A3 (en) Method for drug delivery to the pulmonary system
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE :AVENTIS PHARMCEUTICALS, INC.

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE : HMR PHARMA , INC.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: ANULADA AS PUBLICACOES: COD. DO DESPACHO (25.1) PUBLICADA NAS RPI 2051 DE 27/04/2010 E 2053 DE 11/05/2010 RESPECTIVAMENTE, PARA A LEGALIZACAO DO PROCESSO.

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS PHARMACEUTICALS, INC.

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE: HMR PHARMA, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/00

Ipc: C07K 19/00 (2006.01), C07K 14/47 (2006.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/08/2021